FREQUENCY THERAPEUTICS, INC. (FREQ) News
Filter FREQ News Items
FREQ News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest FREQ News From Around the Web
Below are the latest news stories about Frequency Therapeutics Inc that investors may wish to consider to help them evaluate FREQ as an investment opportunity.
One Frequency Therapeutics, Inc. (NASDAQ:FREQ) insider upped their stake in the previous yearLooking at Frequency Therapeutics, Inc.'s ( NASDAQ:FREQ ) insider transactions over the last year, we can see that... |
Frequency Therapeutics to Present 2022 Business and Pipeline Overview at the 40th Annual J.P. Morgan Healthcare ConferenceLEXINGTON, Mass., January 04, 2022--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function, today announced that Chief Executive Officer David L. Lucchino will present a Company overview at the 40th Annual J.P. Morgan Healthcare Conference. |
Destra Investment Trust Buys ThredUp Inc, Etsy Inc, Riskified, Sells , , 2U IncInvestment company Destra Investment Trust (Current Portfolio) buys ThredUp Inc, Etsy Inc, Riskified, Luxfer Holdings PLC, Spero Therapeutics Inc, sells , , 2U Inc, Euronet Worldwide Inc, Sapiens International Corp NV during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Destra Investment Trust. |
Frequency Therapeutics: FX-322 Associated With Hearing Signal In Placebo-controlled Trial(RTTNews) - Frequency Therapeutics, Inc. (FREQ) reported the results from its FX-322-113 study, a placebo-controlled trial evaluating the administration of FX-322 in subjects with severe sensorineural hearing loss. In the study, FX-322 was associated with a hearing signal as shown by improvements by four subjects in a sentence-in-noise test. |
Frequency Therapeutics' Hearing Loss Candidate Shows Improved Speech Perception In NoiseFrequency Therapeutics Inc (NASDAQ: FREQ) shared the results from its FX-322-113 study of FX-322 in severe sensorineural hearing loss (SNHL). The Phase 1b study, FX-322, was associated with a hearing signal, as shown by improvements by four subjects in a sentence-in-noise test. In the FX-322-113 study, BKB-SIN test improvements were observed in four subjects, all of whom exceeded the 95% critical difference of 3.1 dB SNR, with two subjects showing a 6 dB response. A single placebo patient had a |
Frequency Therapeutics Shares Results from FX-322-113 Severe Sensorineural Hearing Loss Study Showing Speech Perception Improvements in NoiseLEXINGTON, Mass., December 09, 2021--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function, today shared the results from its FX-322-113 study, a placebo-controlled trial evaluating the administration of FX-322 in subjects with severe sensorineural hearing loss (SNHL). In the study, FX-322 was associated with a hearing signal as shown by improvements b |
Millennium Management LLC Has $1.88 Million Position in Frequency Therapeutics, Inc. (NASDAQ:FREQ)Millennium Management LLC increased its stake in shares of Frequency Therapeutics, Inc. (NASDAQ:FREQ) by 2,460.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 188,802 shares of the companys stock after buying an additional 181,428 shares during the quarter. Millennium Management [] |
B.Riley Financial Thinks Frequency Therapeutics’ Stock is Going to RecoverIn a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Frequency Therapeutics (FREQ – Research Report), with a price target of $21.00. The company's shares closed last Tuesday at $5.10, close to its 52-week low of $5.06. According to TipRanks.com, Mamtani is a 3-star analyst with an average return of 2.5% and a 38.2% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Spectrum Pharmaceuticals, and Madrigal Pharmaceuticals. Frequency Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $13.00. |
Frequency Therapeutics (NASDAQ:FREQ) investors are sitting on a loss of 81% if they invested a year agoThe art and science of stock market investing requires a tolerance for losing money on some of the shares you buy. But... |
UBS Asset Management Americas Inc. Increases Stake in Frequency Therapeutics, Inc. (NASDAQ:FREQ)UBS Asset Management Americas Inc. grew its position in Frequency Therapeutics, Inc. (NASDAQ:FREQ) by 151.5% during the 2nd quarter, HoldingsChannel reports. The fund owned 40,496 shares of the companys stock after purchasing an additional 24,396 shares during the period. UBS Asset Management Americas Inc.s holdings in Frequency Therapeutics were worth $403,000 at the end of [] |